{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T07:03:17Z","timestamp":1791442997526,"version":"4.3.3"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,3,28]],"date-time":"2012-03-28T00:00:00Z","timestamp":1332892800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1186\/1471-244x-12-26","type":"journal-article","created":{"date-parts":[[2012,3,28]],"date-time":"2012-03-28T08:31:42Z","timestamp":1332923502000},"source":"Crossref","is-referenced-by-count":47,"title":["A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia"],"prefix":"10.1186","volume":"12","author":[{"given":"Danielle","family":"Coppola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanning","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srihari","family":"Gopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Remmerie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh N","family":"Samtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W","family":"Hough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Nuamah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Sulaiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gahan","family":"Pandina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,3,28]]},"reference":[{"key":"978_CR1","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1176\/appi.ps.55.9.997","volume":"55","author":"SJ Keith","year":"2004","unstructured":"Keith SJ, Pani L, Nick B, Emsley R, San L, Turner M, Conley R, Scully P, Chue PS, Lachaux B: Practical application of pharmacotherapy with long-acting risperidone for patients with schizophrenia. Psychiatr Serv. 2004, 55: 997-1005. 10.1176\/appi.ps.55.9.997.","journal-title":"Psychiatr Serv"},{"key":"978_CR2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0924-977X(97)00045-X","volume":"8","author":"JM Kane","year":"1998","unstructured":"Kane JM, Aguglia E, Altamura AC: Guidelines for depot antipsychotic treatment in schizophrenia. Eur Neuropsychopharmacol. 1998, 8: 55-66. 10.1016\/S0924-977X(97)00045-X.","journal-title":"Eur Neuropsychopharmacol"},{"key":"978_CR3","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/j.1600-0447.2006.00982.x","volume":"115","author":"H Nasrallah","year":"2007","unstructured":"Nasrallah H: The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatr Scand. 2007, 115: 260-267. 10.1111\/j.1600-0447.2006.00982.x.","journal-title":"Acta Psychiatr Scand"},{"key":"978_CR4","doi-asserted-by":"publisher","first-page":"919","DOI":"10.2147\/NDT.S3311","volume":"4","author":"M Rainer","year":"2008","unstructured":"Rainer M: Risperidone long-acting injection: a review of its long term safety and efficacy. Neuropsych Dis Treat. 2008, 4: 919-927.","journal-title":"Neuropsych Dis Treat"},{"key":"978_CR5","first-page":"216","volume":"22","author":"MN Samtani","year":"2009","unstructured":"Samtani MN, Sliwa JK, Haskins JT, Alphs L, Stuyckens K, Herben V, Vermeulen A: Initiation dosing of deltoid intramuscular paliperidone palmitate in schizophrenia: pharmacokinetic rationale based on modeling and simulation. J Pharm Pract. 2009, 22: 216-217.","journal-title":"J Pharm Pract"},{"issue":"Suppl 6","key":"978_CR6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/1359786806071248","volume":"20","author":"HA Nasrallah","year":"2006","unstructured":"Nasrallah HA, Lasser R: Improving patient outcomes in schizophrenia: achieving remission. J Psychopharmacol. 2006, 20 (Suppl 6): 57-61.","journal-title":"J Psychopharmacol"},{"issue":"Suppl 14","key":"978_CR7","first-page":"27","volume":"68","author":"JM Kane","year":"2007","unstructured":"Kane JM: Treatment strategies to prevent relapse and encourage remission. J Clin Psychiatry. 2007, 68 (Suppl 14): 27-30.","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"978_CR8","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.eurpsy.2008.12.002","volume":"24","author":"J Olivares","year":"2009","unstructured":"Olivares J, Rodriguez-Morales A, Diels J, Povey M, Jacobs A, Zhao Z, Lam A: Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry. 2009, 24 (5): 287-296. 10.1016\/j.eurpsy.2008.12.002.","journal-title":"Eur Psychiatry"},{"key":"978_CR9","unstructured":"Invega\u00ae Sustenna\u2122 Prescribing Information last update July 2009, accessed on 28 Dec, 2009."},{"issue":"6","key":"978_CR10","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.pnpbp.2009.05.014","volume":"33","author":"D Hough","year":"2009","unstructured":"Hough D, Lindenmayer JP, Gopal S, Melkote R, Lim P, Herben V, Yuen E, Eerdekens M: Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2009, 33 (6): 1022-1031. 10.1016\/j.pnpbp.2009.05.014.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"978_CR11","doi-asserted-by":"publisher","first-page":"585","DOI":"10.2165\/11316870-000000000-00000","volume":"48","author":"MN Samtani","year":"2009","unstructured":"Samtani MN, Vermeulen A, Stuyckens K: Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia. A novel once-monthly, long-acting formulation of an atypical antipsychotic. Clin Pharmacokinet. 2009, 48: 585-600. 10.2165\/11316870-000000000-00000.","journal-title":"Clin Pharmacokinet"},{"key":"978_CR12","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1185\/03007990903482772","volume":"26","author":"S Gopal","year":"2010","unstructured":"Gopal S, Gassmann-Mayer C, Palumbo J, Samtani MN, Shiwach R, Alphs L: Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia. Curr Med Res Opin. 2010, 26: 377-387. 10.1185\/03007990903482772.","journal-title":"Curr Med Res Opin"},{"key":"978_CR13","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/BF01060893","volume":"9","author":"LB Sheiner","year":"1981","unstructured":"Sheiner LB, Beal SL: Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981, 9: 503-512. 10.1007\/BF01060893.","journal-title":"J Pharmacokinet Biopharm"},{"key":"978_CR14","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/BF02353487","volume":"24","author":"R Bruno","year":"1996","unstructured":"Bruno R, Vivier N, Vergniol JC, De Phillips SL, Montay G, Sheiner LB: A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J Pharmacokinet Biopharm. 1996, 24: 153-172. 10.1007\/BF02353487.","journal-title":"J Pharmacokinet Biopharm"},{"key":"978_CR15","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1128\/AAC.42.5.1098","volume":"42","author":"SL Preston","year":"1998","unstructured":"Preston SL, Drusano GL, Berman AL, Fowler CL, Chow AT, Dornseif B, Reichl V, Natarajan J, Wong FA, Corrado M: Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection. Antimicrob Agents Chemother. 1998, 42: 1098-1104.","journal-title":"Antimicrob Agents Chemother"},{"key":"978_CR16","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1192\/bjp.154.5.672","volume":"154","author":"TR Barnes","year":"1989","unstructured":"Barnes TR: A rating scale for drug-induced akathisia. Br J Psychiatry. 1989, 154: 672-676. 10.1192\/bjp.154.5.672.","journal-title":"Br J Psychiatry"},{"key":"978_CR17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","volume":"212","author":"GM Simpson","year":"1970","unstructured":"Simpson GM, Angus JW: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970, 212: 11-19.","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"978_CR18","volume-title":"ECDEU Assessment Manual for Psychopharmacology, revised, U.S. Department of Health, Education, and Welfare publication (ADM) 76-338","author":"W Guy","year":"1976","unstructured":"Guy W: ECDEU Assessment Manual for Psychopharmacology, revised, U.S. Department of Health, Education, and Welfare publication (ADM) 76-338. 1976, Rockville, MD: National Institute of Mental Health"},{"key":"978_CR19","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay SR, FiszbeinL A, Opler L: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987, 13: 261-276.","journal-title":"Schizophr Bull"},{"key":"978_CR20","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1600-0447.2000.tb10933.x","volume":"101","author":"PL Morosini","year":"2000","unstructured":"Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R: Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand. 2000, 101: 323-329.","journal-title":"Acta Psychiatr Scand"},{"issue":"2","key":"978_CR21","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.schres.2009.10.026","volume":"116","author":"D Hough","year":"2010","unstructured":"Hough D, Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M: Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res. 2010, 116 (2): 107-117. 10.1016\/j.schres.2009.10.026.","journal-title":"Schizophr Res"},{"issue":"5","key":"978_CR22","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1017\/S1461145709990988","volume":"13","author":"M Kramer","year":"2010","unstructured":"Kramer M, Litman R, Hough D, Lane R, Lim P, Liu Y, Eerdekens M: Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. Int J Neuropsychopharmacol. 2010, 13 (5): 635-647. 10.1017\/S1461145709990988.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"3","key":"978_CR23","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/JCP.0b013e3181dd3103","volume":"30","author":"GJ Pandina","year":"2010","unstructured":"Pandina GJ, Lindenmayer JP, Lull J, Lim P, Gopal S, Herben V, Kusumakar V, Yuen E, Palumbo J: Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Doses of Paliperidone Palmitate in Adults with Acutely Exacerbated Schizophrenia. J Clin Psychopharmacol. 2010, 30 (3): 235-244. 10.1097\/JCP.0b013e3181dd3103.","journal-title":"J Clin Psychopharmacol"},{"issue":"10","key":"978_CR24","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1038\/npp.2010.79","volume":"35","author":"HA Nasrallah","year":"2010","unstructured":"Nasrallah HA, Gopal S, Gassmann-Mayer C, Quiroz JA, Lim P, Eerdekens M, Yuen E, Hough D: A controlled, evidence-based trial of paliperidone palmitate, an investigational long-acting injectable antipsychotic, in schizophrenia. Neuropsychopharmacology. 2010, 35 (10): 2072-2082. 10.1038\/npp.2010.79.","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"978_CR25","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1097\/YIC.0b013e32833948fa","volume":"25","author":"S Gopal","year":"2010","unstructured":"Gopal S, Hough DW, Xu H, Lull JM, Gassmann-Mayer C, Remmerie BM, Eerdekens MH, Brown DW: Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study. Int Clin Psychopharmacol. 2010, 25 (5): 247-256. 10.1097\/YIC.0b013e32833948fa.","journal-title":"Int Clin Psychopharmacol"},{"issue":"Suppl 16","key":"978_CR26","first-page":"34","volume":"64","author":"JM Kane","year":"2003","unstructured":"Kane JM: Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies. J Clin Psychiatry. 2003, 64 (Suppl 16): 34-40.","journal-title":"J Clin Psychiatry"},{"key":"978_CR27","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1093\/schbul\/sbm033","volume":"33","author":"M Olfson","year":"2007","unstructured":"Olfson M, Marcus SC, Ascher-Svanum H: Treatment of schizophrenia with longacting fluphenazine, haloperidol, or risperidone. Schizophr Bull. 2007, 33: 1379-1387.","journal-title":"Schizophr Bull"},{"key":"978_CR28","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.clpt.2005.12.265","volume":"79","author":"P Karlsson","year":"2006","unstructured":"Karlsson P, Dencker E, Nyberg S, Mannaert E, Boom S, Talluri K, Rossenu S, Eriksson B, Eerdekens M, Farde L: Pharmacokinetics and dopamine D2 and serotonin 5-HT2A receptor occupancy of paliperidone in healthy subjects: Two open-label single-dose studies. Clin Pharm Ther. 2006, 79: 74-Abstract PIII-57","journal-title":"Clin Pharm Ther"},{"key":"978_CR29","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1176\/ajp.152.2.173","volume":"152","author":"S Nyberg","year":"1995","unstructured":"Nyberg S, Farde L, Halldin C, Dahl ML, Bertilsson L: D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am J Psychiatry. 1995, 152: 173-178.","journal-title":"Am J Psychiatry"},{"key":"978_CR30","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/BF02245603","volume":"457","author":"S Kapur","year":"1996","unstructured":"Kapur S: 5-HT2 antagonism and EPS benefits: is there a causal connection?. Psychopharmcol. 1996, 457: 35-39.","journal-title":"Psychopharmcol"},{"issue":"7","key":"978_CR31","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1176\/ajp.155.7.921","volume":"155","author":"S Kapur","year":"1998","unstructured":"Kapur S, Zipursky RB, Remington G, Jones C, DaSilva J, Wilson AA, Houle S: 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry. 1998, 155 (7): 921-928.","journal-title":"Am J Psychiatry"},{"key":"978_CR32","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1176\/appi.ajp.157.4.514","volume":"157","author":"S Kapur","year":"2000","unstructured":"Kapur S, Zipursky R, Jones C, Remington G, Houle S: Relationship between dopamine D2 occupancy, clinical response, and side effects: A double-blind pet study of first-episode schizophrenia. Am J Psychiatry. 2000, 157: 514-520. 10.1176\/appi.ajp.157.4.514.","journal-title":"Am J Psychiatry"},{"key":"978_CR33","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1176\/appi.ajp.163.3.396","volume":"163","author":"G Remington","year":"2006","unstructured":"Remington G, Mamo D, Labelle A, Reiss J, Shammi C, Mannaert E, Mann S, Kapur S: A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. Am J Psychiatry. 2006, 163: 396-401. 10.1176\/appi.ajp.163.3.396.","journal-title":"Am J Psychiatry"},{"issue":"10","key":"978_CR34","first-page":"829","volume":"25","author":"MN Samtani","year":"2011","unstructured":"Samtani MN, Gopal S, Mayer CG, Alphs L, Palumbo JM: Dosing and switching strategies for paliperidone palmitate: Based on population pharmacokinetic modelling and clinical trial data. CNS Drugs. 2011, 25 (10): 829-845.","journal-title":"CNS Drugs"},{"key":"978_CR35","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","volume":"156","author":"DB Allison","year":"1999","unstructured":"Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ: Antipsychotic-induced weight gain: A comprehensive research synthesis. Am J Psychiatry. 1999, 156: 1686-1696.","journal-title":"Am J Psychiatry"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-12-26.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-244X-12-26\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-12-26","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T10:11:34Z","timestamp":1687342294000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/1471-244X-12-26"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,28]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["978"],"URL":"https:\/\/doi.org\/10.1186\/1471-244x-12-26","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,28]]},"article-number":"26"}}